MIAT in HCC negatively correlates with tumor purity but positively with immune cells (B cells, T lymphocytes, macrophages) and checkpoint molecules (PD-1, PD-L1, CTLA4). MIAT-TF interactions regulate genes (JAK2, SLC6A6, KCND1, MEIS3, RIN1) to influence the immune microenvironment and are linked to sensitivity to anticancer drugs, particularly Sorafenib. The gene discussed is MEIS3; the disease is hepatocellular carcinoma.